Approval of Unaudited Financial Results for the quarter and nine months ended 31-12-2025
KPL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kwality Pharmaceuticals reported strong Q3 FY26 consolidated revenue of ₹123 crore, up 46% year-on-year, driven by robust demand in international markets. For the first nine months of FY26, revenue rose to ₹346 crore from ₹255 crore (up ~36%). EBITDA grew 67% YoY in Q3 to ₹30 crore, with margins expanding from 22.0% to 24.3%. Profit after tax surged 78% in Q3 to ₹16 crore and 68% for 9M FY26 to ₹42 crore. An exceptional item of ₹82.94 lakhs was booked for the new Labour Code's impact on past service gratuity cost. The auditor (Vijay Mehra & Co.) issued a clean limited review report with no qualifications. The subsidiary in Africa is not material. Capex for biologics, oncology and hormone facilities is on track, funded through internal accruals.
Strong across-the-board growth in revenue, EBITDA and PAT with margin expansion signals solid operational momentum. Investors should note the positive guidance of ~₹500 crore FY26 and ~₹650 crore FY27 revenue targets, which could support the stock if execution continues; the Labour Code-related exceptional charge is a one-time, non-cash item and does not weaken the underlying story.